Dr. Palanca-Wessels is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
916 23rd Ave East
Seattle, WA 98112
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2008- University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
- University of WashingtonResidency, Internal Medicine, 2001 - 2003
- University of Washington School of MedicineClass of 2001
Certifications & Licensure
WA State Medical License 2003 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 214 citationsBrentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter
Blood. 2015-02-26 - 367 citationsBrentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, Youn H. Kim, Steven M. Horwitz, Reinhard Dummer, Julia Scarisbrick
Lancet. 2017-08-05 - 215 citationsSafety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaem...Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn
The Lancet. Oncology. 2015-06-01
Press Mentions
ALCANZA Study: Brentuximab Vedotin Superior in CD30-Expressing Cutaneous T Cell LymphomaDecember 3rd, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
